In recognition of the highest achievers in the Australian life sciences sector, the prestigious Industry Excellence Awards were announced today at the AusBiotech 2021 national conference, during Australia’s biggest week of biotech.
The AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards celebrate life science leaders who are championing the sector throughout Australia and the global community. From researchers who successfully translate their discoveries to clinical practice, to companies who pioneer the developments of new treatments and reliable diagnostics, these illustrious Awards recognise the leading lights of Australia’s world-class biotechnology, medical technology and healthcare sectors.
AusBiotech’s Chief Executive Officer, Lorraine Chiroiu, said: “Congratulations to the recipients of the 2021 AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards, who represent the leading success stories of Australian biotechnology and act as a celebration of the innovation excellence happening across the country. The companies and individuals recognised have made an invaluable contribution to the sector and Australia over the years, are driven by passion for innovation and technical excellence in biotechnology, and demonstrate what can be achieved when vision and commitment unite.”
Ms Kathy Connell, Senior Director Early Innovation Partnering, ANZ, Johnson & Johnson Innovation, who announced the Awards, said: “These inspiring award recipients are undertaking an incredibly important mission, aiming to improve the health of people across the globe. We are delighted to sponsor these awards for the ninth consecutive year, and to help recognise the innovative and outstanding approaches to science and business, and the meaningful contributions these biotechnology leaders have made to the Australian life sciences ecosystem.”
About the 2021 winners
- Australian Company of the Year: SpeeDx
Already experiencing strong growth, NSW-based molecular diagnostics company SpeeDx has demonstrated agility throughout the COVID19 pandemic – almost doubling its staff and increasing manufacturing capabilities by over 500 per cent to meet demand for production of COVID-related products, namely tests for detecting the causative agent and/or for genotyping variants of concern.
